



FORM PTO-1449

(Rev. 2-12)

U.S. DEPARTMENT OF  
COMMERCE PATENT AND  
TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
5771-P1-01-MGSERIAL NO.  
09/759,777APPLICANT  
MARIA ISABEL GONZALEZ, ET AL.FILING DATE  
January 12, 2001GROUP  
1614

RECEIVED  
SEP 04 2002  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SH	5 2 0 0 4 0 8	4/6/93	Bru-Magniez et al.	514	237.2	
	5 6 5 0 3 9 5	7/22/97	Hurel	514	16	
SH	5 3 6 9 0 9 4	11/29/94	Schally et al.	514	15	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
SH	0 0 3 7 4 6 2	29.06.00	WO				x
	1 0 5 7 8 2 9	06.12.00	Europe				x
	0 0 6 7 7 0 8	16.11.00	WO				x
SH	9 6 2 8 2 1 4	19.09.96	WO				x

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc)

SH	Partial International Search Report, PCT/GB00/01787
	Blommaert et al., "Cholecystokinin Peptidomimetics As Selective CCK-B Antagonists: Design, Synthesis, And In Vitro and In Vivo Biochemical Properties", <u>J. Med. Chem.</u> , Vol. 36, No. 20, 1993, pp 2868-2877
	Sartori et al., "Synthesis and analgesic activities of urea derivatives of $\alpha$ -amino-N-pyridyl benzene propanamide", <u>Eur. J. Med. Chem.</u> , Vol. 29, 1994, pp 431-439
	PCT International Search Report, PCT/GB00/04380
	PCT International Search Report, PCT/GB00/04915
	Ryan et al., "Comparative Pharmacology of the Nonpeptide Neuromedin B Receptor Antagonist PD 168368", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , Vol. 290, No. 3, 1999, pages 1202-1211
	Tokita et al., "Tyrosine 220 in the 5 <sup>th</sup> Transmembrane Domain of the Neuromedin B Receptor Is Critical for the High Selectivity of the Peptoid Antagonist PD168368", <u>The Journal of Biological Chemistry</u> , Vol. 276, No. 1, 2001, pages 495-504
	Various: "The Merck Manual", Beers and Berkow, N.J., page 988
SH	Moody et al., "Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells", <u>European Journal of Pharmacology</u> , Vol. 409, 2000, pages 133-142

EXAMINER-

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ANY COPIES OF DOCUMENTS LISTED ON THIS FORM PTO-1449 SHOULD HAVE CERTAIN INFORMATION PLACED ALONG THE LEFT SIDE OF THE DOCUMENT. INFORMATION SUCH AS DOCKET NUMBER, FILING DATE, SERIAL NUMBER, ART UNIT, ETC.